Literature DB >> 15068615

Role of 99mTc-bombesin scan in diagnosis and staging of prostate cancer.

Giuseppe De Vincentis1, Silvia Remediani, Alexandra D Varvarigou, Gianpaolo Di Santo, Francesco Iori, Cesare Laurenti, Francesco Scopinaro.   

Abstract

Aim of this work was to asses whether a novel 99mTc labeled Bombesin (BN) can play a clinical role in diagnosis and staging of prostate cancer. 14 patients were studied with trans-rectal ultrasonography-guided biopsy, CT and MRI and with 99mTc BN Scintigraphy. Five patients were also imaged by 111In Octreotide (O) scan. All the patients but one were submitted to surgery and final diagnosis was reached by pathology, taken as the gold standard method. Two patients showed benign adenoma and 12 patients showed cancer at biopsy. 99mTc BN SPECT was positive in all 12 patients with cancer. Four of these patients also showed pelvic focal uptake, referred to inguinal lymph-nodal involvement. MRI and CT provided similar findings in only three cases. Pathologic evaluation after operation confirmed the invasion of nodes in all four subjects. Both 99mTc BN and 111In O scans provided normal findings in the two subjects affected by benign adenoma, while 111In O was positive in only two of three patients with cancer and was always unable to detect nodal invasion. These preliminary data suggest that 99mTc BN SPECT scan could be useful to detect primary prostate cancer and to reveal loco-regional node involvement.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15068615     DOI: 10.1089/108497804773391711

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  12 in total

Review 1.  Bombesin receptor-mediated imaging and cytotoxicity: review and current status.

Authors:  Veronica Sancho; Alessia Di Florio; Terry W Moody; Robert T Jensen
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

Review 2.  Techniques for molecular imaging probe design.

Authors:  Fred Reynolds; Kimberly A Kelly
Journal:  Mol Imaging       Date:  2011-12       Impact factor: 4.488

Review 3.  Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment.

Authors:  Paola Moreno; Irene Ramos-Álvarez; Terry W Moody; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2016-03-28       Impact factor: 6.902

Review 4.  Peptide receptors as cancer drug targets.

Authors:  Terry W Moody
Journal:  Ann N Y Acad Sci       Date:  2019-05-10       Impact factor: 5.691

Review 5.  Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm.

Authors:  Hebert Alberto Vargas; Jan Grimm; Olivio F Donati; Evis Sala; Hedvig Hricak
Journal:  Eur Radiol       Date:  2015-02-20       Impact factor: 5.315

Review 6.  Targeting GRPR in urological cancers--from basic research to clinical application.

Authors:  Rosalba Mansi; Achim Fleischmann; Helmut R Mäcke; Jean C Reubi
Journal:  Nat Rev Urol       Date:  2013-03-19       Impact factor: 14.432

Review 7.  Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states.

Authors:  Nieves Gonzalez; Terry W Moody; Hisato Igarashi; Tetsuhide Ito; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2008-02       Impact factor: 3.243

Review 8.  International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states.

Authors:  R T Jensen; J F Battey; E R Spindel; R V Benya
Journal:  Pharmacol Rev       Date:  2007-11-30       Impact factor: 25.468

9.  Radiolabeled nano-peptides show specificity for an animal model of human PC3 prostate cancer cells.

Authors:  Bluma Linkowski Faintuch; Gustavo Eutimio Fernandez Núñez; Rodrigo Teodoro; Ana M Moro; Jair Mengatti
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

10.  Expression of V1A and GRP receptors leads to cellular transformation and increased sensitivity to substance-P analogue-induced growth inhibition.

Authors:  A C MacKinnon; U Tufail-Hanif; C D Lucas; D Jodrell; C Haslett; T Sethi
Journal:  Br J Cancer       Date:  2005-02-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.